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Background
A clinical trial is a research study in 
which human volunteers are treated 
and observed to an  swer a particular 
biomedical question. Clinical trials are 
one of the most valuable sources of 
evidence to determine which therapies 
are safe and effective. However, 
instances of selective re  porting 
of results to beneﬁ  t proprietary 
interests rather than public health 
have recently come to light. For 
example, in 2004, GlaxoSmithKline 
settled a US$2.5 million lawsuit for 
suppressing trial results showing that 
its antidepressant paroxetine (Paxil) 
increased suicidal ideation in children 
[1]. More re  cently, Merck and Pﬁ  zer 
have been criticized for with  holding 
results showing increased risk of heart 
disease from COX-2 drugs such as 
rofecoxib (Vioxx) [2–4], which was 
withdrawn from the market because of 
these risks.
A complete public register of trials 
and the subsequent release of all results 
are crucially impor  tant to prevent drug 
and device makers from skewing the 
public record on the effectiveness of 
therapies. However, even when local 
laws require that trials be registered, 
compliance has been incomplete. 
In the United States, the Food and 
Drug Administration Modernization 
Act [5] requires that all trials on life-
threatening diseases be registered 
into ClinicalTrials.gov (a register 
maintained by the National Institutes 
of Health), yet only 48% of industry-
sponsored trials were registered 
during the initial period of the law’s 
implementation [6]. Moreover, 
trials are sometimes registered with 
uninformative data (e.g., not giving 
the name of the tested drug) [7], 
thus subverting the central purpose 
of registration, which is to increase 
transparency. 
In reaction to this general state of 
affairs, an inﬂ  uential group of medical 
journal editors recently declared 
that they will publish only previously 
registered trials [7,8]. In addition, 
legislation is being introduced in 
many jurisdictions to impose broader 
mandates on trial registration and 
reporting (e.g., Fair Access to Clinical 
Trials Act in the US Congress). The 
World Health Organization (WHO), 
recognizing the highly international 
nature of modern clinical trial conduct, 
is establishing policies and standards 
for trial registration and reporting 
worldwide [9]. A global commitment 
is, thus, emerging to ensure that key 
information about all clinical trials are 
registered, and that each trial’s results 
are fully reported. 
At a time when over 20,000 new trials 
are initiated worldwide each year, and 
with over 294,000 trials already indexed 
in PubMed, careful thought should be 
given to how computers could be used 
to manage the deluge of information. 
The current consensus is to attempt 
to code some of the registration data 
ﬁ  elds (e.g., condition, interventions, 
and outcomes) using a standard 
medical vocabulary (e.g., International 
Classiﬁ  cation of Diseases [10] and 
SNOMED [11]), and to report trial 
results in English in at least a PDF 
version of the International Conference 
on Harmonisation E3 guidelines 
(http:⁄⁄www.ich.org/). However, 
computers cannot read or understand 
prose very well at all. For example, 
the sentence “mean creatinine was 1.9 
(95% conﬁ  dence interval, 1.2–2.6) in 
the intervention group and 2.4 (95% 
conﬁ  dence interval, 1.9–2.9) in the 
comparison group” is not directly 
usable by search engines, statistical 
programs, or decision support 
systems. The prose reporting of trial 
information could be powerfully 
augmented by a computable repository 
of trial information—a global trial 
bank. Unlike prose, computable 
information is structured and coded 
for computation and allows the use of 
advanced information technologies for 
knowledge management. With billions 
of dollars spent annually on drugs and 
other health interventions, the world 
cannot afford to keep knowledge from 
clinical trials only in prose. 
The Global Trial Bank Project
Global Trial Bank (GTB) is a nonproﬁ  t 
organization formed under the 
auspices of the American Medical 
Informatics Association (http:⁄⁄www.
amia.org), a professional scientiﬁ  c 
association. GTB’s goal is to speed 
the dissemi  nation, understanding, 
synthesis, and translation of clinical 
trials to improve human health. To 
reach this goal, GTB seeks to make 
available open-access and computable 
peer-reviewed results from all clinical 
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trials conducted worldwide, regardless 
of whether the results are favorable 
or not, to provide an unbiased 
knowledge base for improving human 
health. Through the GTB Web site 
(http:⁄⁄www.globaltrialbank.org), 
clinicians and patients will be able 
to accurately retrieve relevant trial 
results, and scientists will be able to 
analyze data across trials to compare 
and contrast trials and to generate new 
ﬁ  ndings and insights. The key features 
of GTB are as follows.
Sufﬁ  cient detail for science. GTB 
will collect necessary protocol and 
results information in sufﬁ  cient detail 
to allow the scientiﬁ  c community to 
assess a study’s scientiﬁ  c strengths and 
weaknesses, and to properly interpret 
the ﬁ  ndings. This includes information 
on study design (e.g., allocation 
concealment), study execution (e.g., 
withdrawal rates and compliance), and 
study results (e.g., subgroup results 
and adverse events). The data collected 
will be compatible with the WHO 
Registration Data Set [9] as well as the 
CONSORT statement on trial reporting 
(http:⁄⁄www.consort-statement.org/).
Computable information. GTB will 
collect the following information in 
structured, coded form: eligibility 
criteria, interventions, outcomes, 
and summary results for outcomes 
at all predeﬁ  ned time points for all 
intervention and comparison groups 
and predeﬁ  ned subgroups. GTB will 
then be able to support queries such 
as “retrieve all trials on women over 
age 60 with heart disease in which 
a beta-blocker was studied, and that 
report heart attack rates at three and 
ﬁ  ve years for which at least 80% of 
the participants were followed up.” 
Such detailed queries and analyses will 
enable much more powerful com  puter-
assisted interpretation, application, and 
data mining of clinical trial information 
than is possible today. 
To further support clinical trial 
knowledge management, GTB will 
provide standards-compliant interfaces 
for information and decision support 
systems to directly access the GTB 
database over the Internet. This 
will allow third parties to provide 
customized solutions without having 
to manually transcribe data from text 
articles to another computer.
Integrated peer review. We anticipate 
that protocol information will be 
either downloaded directly from a trial 
register if not registered directly with 
GTB or entered by the trialist. Protocol 
information will not be peer reviewed. 
It is critical, however, that trial results 
be peer reviewed. Results will come 
from three sources: (1) results reported 
in peer-reviewed mainline journals, (2) 
results reported in non-peer-reviewed 
publications or Web sites (e.g., 
pharmaceutical company sites), and (3) 
results reported directly to GTB. 
Results not directly reported to GTB 
will be captured semiautomatically with 
some input by GTB staff and/or the 
trialist. GTB will link to peer-reviewed 
publications and will not perform 
further peer review on these trials. 
There is a precedence, called “trial 
bank publishing” [12], for publishing 
trial results as both prose journal 
articles and trial bank entries. It is 
a model akin to the publication of 
genomic information in both GenBank 
and traditional scientiﬁ  c journals [13]. 
Trial results that have not been 
previously peer reviewed will be 
submitted to PLoS Clinical Trials 
(http:⁄⁄www.plosclinicaltrials.org), a 
new PLoS journal, for peer review. PLoS 
Clinical Trials anticipates accepting 
all trials that meet a set of minimum 
require  ments regardless of outcome 
DOI: 10.1371/journal.pmed.0020365.g001
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or “clinical interest” to maximize the 
number of trials that are reported 
to the public. PLoS will also provide 
annotated commentaries on accepted 
studies and a discussion forum for open 
postpublication peer review of all GTB 
entries of completed trials. 
Promotes transparency, 
interoperation, and open access. GTB 
fully supports international efforts 
to standardize and streamline trial 
registration and reporting. To this 
end, all GTB trials must be registered 
with a WHO-certiﬁ  ed trial register 
using the WHO global unique ID (see 
http:⁄⁄www.who.int/ictrp), and all 
GTB data exchange interfaces will be 
compatible with relevant emerging stan-
dards (e.g., Clinical Data Interchange 
Standards Consortium, Health Level 
Seven, WHO, and Cancer Biomedical 
Informatics Grid). In addition, GTB 
strongly supports open access to clinical 
trial information: patients, clinicians, 
and scientists will be able to search, 
browse, analyze, and download GTB 
data without charge or restriction. 
GTB builds upon the National 
Institutes of Health–funded 
research of the Trial Bank Project 
(http:⁄⁄rctbank.ucsf.edu/) and 
PLoS’s vision of a new, more inclusive 
approach to make peer-reviewed 
clinical trial results available to 
the public. GTB has formed an 
international advisory board and 
received a seed grant, and is actively 
forming additional partnerships and 
seeking foundation funds for start-up. 
Challenges
GTB reﬂ  ects a new approach to 
publishing clinical research: publishing 
in both prose and computable form, 
as well as publishing all results, not 
just “clinically important” ones. 
As such, GTB faces undeniable 
challenges. The work of data entry 
must be reasonable. The coding of 
data ﬁ  elds in a controlled medical 
vocabulary (e.g., SNOMED) must 
be relatively easy and reproducible. 
The publishing model should result 
in overall strengthening of the 
quality and usefulness of clinical trial 
publishing. And ﬁ  nally, the operation 
must be open access yet ﬁ  nancially self-
sustaining. Intermediate solutions to 
these challenges are available and will 
provide opportunities for continuing 
improvement. 
Conclusions
The reporting of clinical trial results 
as both prose and computable data 
is arguably a natural progression 
in the development of electronic 
publishing. Coupled with emerging 
international policies on clinical trial 
registration, GTB offers the most 
advanced computable repository of 
trial protocol and results information 
to promote biomedical discovery as 
well as transparency and accountability 
in clinical trial research. With its 
additional features of being nonproﬁ  t, 
open access, and peer reviewed, we 
anticipate that GTB will become a 
major global resource for knowledge 
management in biomedicine.  
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